Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)

What Was Tested

The trial (phase 3) is built around Semaglutide.

The primary risk factor for coronary artery disease is atherosclerosis, with inflammation playing a crucial role in the development and progression of this condition.

It has now been proven that inflammation is key in the development of complications after an acute myocardial infarction.

These complications can be immediate and mechanical, such as ventricular wall rupture and ventricular arrhythmia, or long-term, presenting as major cardiovascular events like heart failure.

It had two arms (groups): Dapagliflozin (experimental) and Semaglutide (active comparator).

The registry classes the interventions as drug.

More on the Plan

Inflammation markers will be measured upon patient admission after percutaneous coronary intervention and again after 24 weeks of treatment with the drugs.

Patients will be discharged in accordance with STEMI treatment guidelines, and their medication adherence and tolerability will be monitored.

Who Took Part

The registry lists 44 planned participants were the target.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Criteria for the fourth definition of acute myocardial infarction with ST-segment elevation. Diagnosed with type 2 diabetes.

The full record lists 5 inclusion and 10 exclusion criteria; among the exclusions: patients who have recently received immunosuppressive therapy; patients with a history of ischemic heart disease; known allergy to any of the medications used.

How the Study Was Run

The set-up was randomized, parallel-group and open-label.

Random assignment meant chance, not the researchers, decided who got Semaglutide and who got the comparison, which limits bias.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Being open-label, the Semaglutide study did not mask who received what.

It started in 2025-12-30 with completion listed for 2026-08.

It ran at 1 site in Mexico.

Its stated primary purpose is treatment.

What Was Measured

Primary outcome: Inflammatory markers (high-sensitivity PCR) (time frame: 24 weeks). Inflammatory markers (interleukin 6) (time frame: 24 weeks).

It also tracked 3 secondary outcomes, for example Epicardial fat, LDL cholesterol and Change in glucose and HbA1c.

What This Means in Plain Language

Put simply, this is a phase 3, randomized trial of Semaglutide in 44 people.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Semaglutide compound page, all human trials.